NASDAQ · Biotechnology

PBM (PBM) Stock

$3.30 +4.76% NASDAQ: PBM Healthcare

Valuation

MetricValue
Price$3.30
Market Cap$62763
P/E Ratio2.76
P/B Ratio0.01
P/S Ratio0.00
EPS (TTM)$1.78
52-Week High$468.36
52-Week Low$1.92
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE14.29%
ROA14.29%
ROCE-66.67%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio7.00

Annual Financials (USD)

Metric20202021202220232024
Revenue—$0$0$0$0
Operating Profit—$0$-1.0M$-3.0M$-4.0M
Net Profit—$8.0M$8.0M$-51.0M$1.0M
EPS—$0.25$-0.64$-7.85$1.78
Op Margin—————

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$5.0M$256.0M$259.0M$1.0M$7.0M
Total Liabilities$0$16.0M$14.0M$12.0M$1.0M
Cash$5.0M$0$0$1.0M$6.0M
Borrowings$0$0$1.0M$10.0M$0

Latest News

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing GlobeNewswire · May 15, 2026 Weekly Roundup on the Cannabis Sector & Psychedelic Sector Market Exclusive · Apr 27, 2026 FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain MT Newswires · Apr 24, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow—$-1.0M$-1.0M$-3.0M$-4.0M
Investing Cash Flow—$0$0$0$0
Financing Cash Flow—$-258.0M$1.0M$0$0
Net Cash Flow—$-3.0M$0$-1.0M$5.0M
Free Cash Flow$0$-1.0M$-1.0M$-3.0M$-4.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-4274.74%
Quick Ratio7.00
Interest Coverage—
Return 1Y-98.61%
Return 3Y-100.00%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AZTR $0.14 +0.80% -0.09 $1.49M 0.00%
DRMA $1.10 -0.90% -0.15 $749713 0.00%
ELAB $0.92 +2.21% 0.00 $1.78M 0.00%
GTBP $0.29 -4.65% -0.07 $3.12M 0.00%
INDP $1.39 -3.82% -0.06 $2.43M 0.00%

About PBM

PBM is led by CEO Jody Aufrichtig, employs 12 people, headquartered in CA, publicly traded since 2021.

PBM stock trades at $3.30 with a market capitalization of $62763. The stock is valued at a price-to-earnings (P/E) ratio of 2.76, price-to-book of 0.01, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.92 and $468.36, and currently trades 99.3% below its 52-week high.

On profitability, PBM generates a return on equity (ROE) of 14.29%, above the typical market average, return on capital employed of -66.67%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides